ACH

Business Context and Reporting Period

Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: The nation's leading distributor of medical and surgical supplies to the acute-care market and a healthcare supply-chain management company. The company also operates a direct-to-consumer (DTC) business for diabetic testing supplies. In September 2006, the company acquired the acute-care distribution business of McKesson Medical-Surgical Inc. for approximately $168.6 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 14.8% to $5.53 billion, driven by the McKesson acquisition ($282 million contribution), sales to new customers, and volume growth in the DTC segment.
• Profitability Decline: Net income decreased 24% to $48.8 million. This was primarily due to:
  • A $9.3 million pre-tax charge to increase the allowance for doubtful accounts in the DTC business.
  • $16.0 million of dilution related to the McKesson acquisition.
  • $2.6 million in stock-based compensation expenses from the adoption of SFAS 123(R).
  • A $11.4 million loss on the early extinguishment of debt.
• Liquidity Shift: Cash and cash equivalents dropped significantly from $71.9 million to $5.1 million due to the acquisition and working capital build-up for transitioning customers. Operating cash flow turned negative ($73.6 million used) compared to positive $135.4 million in 2005.
• Debt Increase: Long-term debt more than doubled to $433.1 million to fund the McKesson acquisition and working capital needs. The company issued $200 million in 6.35% Senior Notes due 2016 and retired $200 million of 8.5% Senior Subordinated Notes.

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management expects competitive pricing pressures to continue. The company is focusing on margin initiatives through consulting services (OMSolutions) and private label products (MediChoice). The DTC business is growing but faces higher SG&A expenses and credit risks.
• Unusual Items:
  • DTC Credit Charge: A $9.3 million charge for doubtful accounts in the DTC segment due to rapid growth straining systems.
  • Debt Refinancing: $11.4 million loss on early debt retirement.
  • Accounting Changes: Adoption of SFAS 123(R) for share-based compensation and SFAS 158 for pension plan accounting.
• Key Risks:
  • Customer Concentration: 70% of revenue comes from three GPOs (Novation, Broadlane, Premier). Novation alone represented 43% of revenue.
  • Supplier Dependence: Top 10 suppliers accounted for 56% of revenue.
  • Tax Contingency: An IRS dispute regarding LIFO inventory valuation could result in a $71.5 million tax deficiency plus interest if the company loses the appeal.
  • Interest Rate Risk: Exposure to variable rates on the revolving credit facility and interest rate swaps.

Investor Verification Checklist

• IRS LIFO Dispute: Verify the status of the $71.5 million potential tax deficiency and the likelihood of resolution.
• DTC Credit Quality: Assess the adequacy of the allowance for doubtful accounts in the DTC segment following the $9.3 million charge.
• McKesson Integration: Monitor the realization of synergies and the impact of the $16.0 million dilution on future earnings.
• Liquidity Position: Review the company's ability to manage working capital given the low cash balance ($5.1 million) and high debt load.
• GPO Contract Renewals: Track the renewal status of contracts with Novation, Broadlane, and Premier, which represent the majority of revenue.